FSD Pharma is a life sciences holding company dedicated to building a portfolio of diversified therapeutic assets and innovative healthcare and biotech services. The Company is currently advancing a pipeline of innovative therapeutics that target Total Brain Health with multiple lead clinical candidates addressing a variety of neurodegenerative and neuropsychiatric diseases.
Through its wholly-owned subsidiary, Lucid Psycheceuticals, FSD has exclusive worldwide rights to novel compounds shown to reverse the underlying cause of progressive Multiple Sclerosis. Additionally, FSD is developing a unique psychedelic-based therapeutic aimed to address a multibillion-dollar mental health market. The Company plans to quickly advance its lead drug candidates through clinical trials to one day change the minds and bodies of millions of patients for the better.
Sector:
Healthcare
Industry:
Drug Manufacturers
NAICS:
Pharmaceutical
Preparation
Manufacturing (325412)
SIC:
Pharmaceutical and
Medicine Industry
(3741)
Q1 2022
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL STATEMENTS
for the three months ended March 31, 2022, and 2021
|
|
What is FSD Pharma Inc.'s stock symbol?
Our stock is traded on the CSE under the symbol HUGE and on the Nasdaq under the symbol HUGE.When was FSD Pharma Inc. incorporated?
November 1, 1998When did FSD Pharma Inc. become a public company?
May 29, 2018When is FSD Pharma Inc.'s fiscal year end?
December 31stWho is FSD Pharma Inc.'s transfer agent?
Marrelli Support Services Inc. (MSSI)Who is FSD Pharma Inc.'s independent auditor?
MNP LLPWho is FSD Pharma Inc.'s outside legal counsel?
Blake, Cassels & Graydon LLPReceive most valuable updates straight into your inbox
SIGN UP TODAY
PLEASE SEND INVESTOR INQUIRIES TO [email protected],
ALL OTHER INQUIRIES PLEASE EMAIL TO [email protected]@FSDPHARMA.COM
JOIN OUR TEAM
Careers